Inovio Pharmaceuticals, Inc. (INO) Given Average Rating of “Hold” by Analysts
Inovio Pharmaceuticals, Inc. (NASDAQ:INO) has been given an average recommendation of “Hold” by the thirteen ratings firms that are currently covering the company, Marketbeat Ratings reports. Two investment analysts have rated the stock with a sell rating, three have given a hold rating and eight have issued a buy rating on the company. The average 12 month price target among analysts that have updated their coverage on the stock in the last year is $20.20.
Several research analysts have commented on INO shares. HC Wainwright set a $13.00 target price on Inovio Pharmaceuticals and gave the stock a “buy” rating in a research note on Friday, July 7th. Zacks Investment Research upgraded Inovio Pharmaceuticals from a “hold” rating to a “buy” rating and set a $8.75 target price for the company in a research note on Tuesday, July 11th. Aegis restated a “buy” rating and issued a $14.00 target price on shares of Inovio Pharmaceuticals in a research note on Tuesday, July 18th. BidaskClub downgraded Inovio Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Friday, July 28th. Finally, Maxim Group set a $12.00 target price on Inovio Pharmaceuticals and gave the stock a “buy” rating in a research note on Wednesday, August 9th.
Several institutional investors and hedge funds have recently modified their holdings of INO. BlueCrest Capital Management Ltd bought a new stake in shares of Inovio Pharmaceuticals during the 2nd quarter valued at about $107,000. PNC Financial Services Group Inc. boosted its position in shares of Inovio Pharmaceuticals by 5.0% during the 2nd quarter. PNC Financial Services Group Inc. now owns 21,000 shares of the biopharmaceutical company’s stock valued at $164,000 after acquiring an additional 1,000 shares during the last quarter. Northwestern Mutual Wealth Management Co. bought a new stake in shares of Inovio Pharmaceuticals during the 2nd quarter valued at about $171,000. Bank of America Corp DE boosted its position in shares of Inovio Pharmaceuticals by 14.6% during the 1st quarter. Bank of America Corp DE now owns 28,256 shares of the biopharmaceutical company’s stock valued at $188,000 after acquiring an additional 3,605 shares during the last quarter. Finally, OxFORD Asset Management LLP bought a new stake in shares of Inovio Pharmaceuticals during the 2nd quarter valued at about $194,000. Hedge funds and other institutional investors own 24.83% of the company’s stock.
Shares of Inovio Pharmaceuticals (INO) traded down 4.98% during midday trading on Wednesday, hitting $5.92. 1,628,410 shares of the stock were exchanged. Inovio Pharmaceuticals has a 1-year low of $5.28 and a 1-year high of $9.86. The stock’s 50-day moving average price is $6.22 and its 200-day moving average price is $6.64. The firm’s market capitalization is $534.14 million.
Inovio Pharmaceuticals (NASDAQ:INO) last posted its quarterly earnings results on Tuesday, August 8th. The biopharmaceutical company reported ($0.13) earnings per share for the quarter, topping the consensus estimate of ($0.21) by $0.08. The company had revenue of $20.41 million during the quarter, compared to the consensus estimate of $16.29 million. Inovio Pharmaceuticals had a negative return on equity of 63.67% and a negative net margin of 153.46%. The firm’s quarterly revenue was up 229.2% compared to the same quarter last year. During the same quarter in the prior year, the company earned ($0.26) EPS. On average, analysts forecast that Inovio Pharmaceuticals will post ($0.95) EPS for the current year.
Inovio Pharmaceuticals Company Profile
Inovio Pharmaceuticals, Inc (Inovio) is a clinical-stage pharmaceutical company, which is involved in developing deoxyribonucleic acid (DNA) immunotherapies and vaccines focused on treating and preventing cancers and infectious diseases. The Company’s DNA-based immunotherapies, in combination with its electroporation delivery devices, generates immune responses, in particular T cells, in the body to fight target diseases.
Receive News & Ratings for Inovio Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inovio Pharmaceuticals Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.